Retatrutide
Triple-receptor agonist. The mortal weakness yields.
- Sizes available
- 5mg · 10mg · 15mg · 20mg · 30mg · 50mg · 60mg
- Lab certificate (COA)
- Supplier-published sample
· Research-grade only · Not for human consumption · 21+ ·
Investigational fat-loss and appetite-suppression therapy. Weekly subcutaneous injection. 12-week starting cycle.
Mechanism · Triple-receptor agonist (GLP-1 + GIP + glucagon). Phase 2 obesity trial (NCT05971940).
Best for. Not for.
Best for
- Aggressive fat-loss goals with a 12-week-plus commitment.
- Plateau on tirzepatide or semaglutide monotherapy.
- Appetite control is the primary obstacle to a diet.
Not for
- Personal or family history of medullary thyroid carcinoma or MEN-2 (GLP-1 class warning).
- Pancreatitis, gallstones, or significant GI motility disorders.
- Pregnancy, nursing, or planned pregnancy.
- Type 1 diabetes or elevated DKA risk.
- BMI <25 outside of a documented fat-loss objective (out of research scope).
Mechanism, dose, ramp, risk.
- Mechanism
- Triple-receptor agonist (GLP-1 + GIP + glucagon) for body recomposition.Source · Mounjaro/Wegovy ATC-class analog
- Target dose
- 3 mg / week by week 5.Source · PEPVERA editorial
- Ramp
- 12 weeks. Begin at 0.25 mg.Source · PEPVERA editorial
- Risks
- Anxiety and nausea are common during ramp; a slow titration mitigates both.Source · PEPVERA note
Compared to its siblings.
Retatrutide
Investigational fat-loss and appetite-suppression therapy. Weekly subcutaneous injection. 12-week starting cycle.
Pros
- · Greater fat-loss potency than tirzepatide in Phase 2 head-to-head (~24% vs ~21%).
- · Glucagon arm raises resting energy expenditure beyond tirzepatide and semaglutide.
- · Lower plateau and weight-regain rate than semaglutide (STEP).
Cons
- · No FDA approval; still Phase 2.
- · Less long-term safety data than semaglutide or tirzepatide.
- · Higher cost and tighter supply than semaglutide.
Tirzepatide
GLP-1 + GIP. No glucagon arm. FDA approved (Mounjaro / Zepbound).
Pros
- · FDA approval (Mounjaro / Zepbound) with a larger evidence base.
- · Broad SURMOUNT Phase 3 dataset.
Cons
- · Lower fat-loss potency in the Phase 2 head-to-head.
- · Weight-loss plateau arrives sooner.
See Tirzepatide →
Semaglutide
GLP-1 only. First-gen incretin. FDA approved (Wegovy / Ozempic).
Pros
- · The widest clinical and long-term dataset.
- · Stable supply and lower cost.
Cons
- · Lower fat-loss potency than retatrutide or tirzepatide.
- · Higher plateau and weight-regain rate (STEP trials).
See Semaglutide →
COA per supplier
Published, in-house, or shipment-time
Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.
Compare 11 suppliers
| Supplier | Price | COA | Ships | |
|---|---|---|---|---|
| Royal PeptidesUS | $55$11.00/mg · 5mg | Sample COA published | 3 days | |
| Pure Peptide UKUK | $75$7.50/mg · 10mg | In-house COA | 4 days | Out of stock |
| Royal PeptidesUS | $80$8.00/mg · 10mg | Sample COA published | 3 days | |
| Royal PeptidesUS | $105$7.00/mg · 15mg | Sample COA published | 3 days | |
| Royal PeptidesUS | $135$6.75/mg · 20mg | Sample COA published | 3 days | |
| Orion PeptidesUS | $149.99$10.00/mg · 15mg | COA with shipment | 3 days | Out of stock |
| Royal PeptidesUS | $185$6.17/mg · 30mg | Sample COA published | 3 days | |
| Orion PeptidesUS | $189.99$9.50/mg · 20mg | COA with shipment | 3 days | Out of stock |
| Orion PeptidesUS | $234.99$7.83/mg · 30mg | COA with shipment | 3 days | Out of stock |
| Royal PeptidesUS | $285$5.70/mg · 50mg | Sample COA published | 3 days | |
| Royal PeptidesUS | $330$5.50/mg · 60mg | Sample COA published | 3 days |
Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.
Risk
Anxiety and nausea are common during ramp; a slow titration mitigates both. These pass with discipline. They do not pass with bravado.
Source · PEPVERA noteDiscipline
12 weeks. Begin at 0.25 mg.
Source · PEPVERA editorialWellness
Hydrate. Eat protein. Sleep eight. Hold a dose for at least two weeks before ascending.
Anti-patterns
- · Do not pair with stimulants late in the day.
- · Do not break the cycle without a planned taper.
- · Do not exceed the dose to chase a deeper sleep response.
Crisis
If the ramp triggers severe anxiety, anhedonia, or persistent gastrointestinal disturbance, stop. Resume after two weeks at half the prior dose. The discipline is the slow climb.
Week 1–2
0.25 mg / wk
Baseline ramp
Week 3–4
0.5 mg / wk
Hold, observe
Week 5–8
1.0–2.0 mg / wk
Ascend
Week 9–12
3 mg / week by week 5.
Terminus
Draw 20 units.
0.5 mg = 0.20 mL at 2.50 mg/mL. 10.0 doses per vial.
cut · I · Royal Peptides
Retatrutide · 5mg